226 related articles for article (PubMed ID: 15075385)
1. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
[TBL] [Abstract][Full Text] [Related]
2. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
3. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.
Bessho Y; Oguri T; Achiwa H; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Cancer Sci; 2006 Mar; 97(3):192-8. PubMed ID: 16542215
[TBL] [Abstract][Full Text] [Related]
4. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
5. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Liao Z; Robey RW; Guirouilh-Barbat J; To KK; Polgar O; Bates SE; Pommier Y
Mol Pharmacol; 2008 Feb; 73(2):490-7. PubMed ID: 17984197
[TBL] [Abstract][Full Text] [Related]
7. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
8. Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Robey RW; Steadman K; Polgar O; Morisaki K; Blayney M; Mistry P; Bates SE
Cancer Res; 2004 Feb; 64(4):1242-6. PubMed ID: 14973080
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
10. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
11. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Chang CH; Wang Y; Zalath M; Liu D; Cardillo TM; Goldenberg DM
Mol Cancer Ther; 2016 Aug; 15(8):1910-9. PubMed ID: 27207776
[TBL] [Abstract][Full Text] [Related]
12. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
14. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
15. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
Yoshikawa M; Ikegami Y; Sano K; Yoshida H; Mitomo H; Sawada S; Ishikawa T
J Exp Ther Oncol; 2004 Apr; 4(1):25-35. PubMed ID: 15255290
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.
Lansiaux A; Facompré M; Wattez N; Hildebrand MP; Bal C; Demarquay D; Lavergne O; Bigg DC; Bailly C
Mol Pharmacol; 2001 Sep; 60(3):450-61. PubMed ID: 11502875
[TBL] [Abstract][Full Text] [Related]
17. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
18. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Arnaud O; Boumendjel A; Gèze A; Honorat M; Matera EL; Guitton J; Stein WD; Bates SE; Falson P; Dumontet C; Di Pietro A; Payen L
Eur J Cancer; 2011 Mar; 47(4):640-8. PubMed ID: 21216589
[TBL] [Abstract][Full Text] [Related]
19. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
de Jong FA; Marsh S; Mathijssen RH; King C; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2004 Sep; 10(17):5889-94. PubMed ID: 15355921
[TBL] [Abstract][Full Text] [Related]
20. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
